PROMIS NEUROSCIENCES INC (PMN) Stock News

USA - NASDAQ:PMN - CA74346M4065 - Common Stock

0.416 USD

-0.02 (-5.02%)

Last: 10/29/2025, 6:02:11 PM

0.4183 USD

+0 (+0.55%)

After Hours: 10/29/2025, 6:02:11 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PMN Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

7 days ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

2 months ago - By: Benzinga - Mentions: MEIP IMCC SSKN GNPX ...

12 Health Care Stocks Moving In Friday's After-Market Session

2 months ago - By: Benzinga - Mentions: NBY PHR IMCC MODD ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

2 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

2 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Private Placement Financing

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Private Placement Financing

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Private Placement Financing

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Private Placement Financing

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

3 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

4 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

6 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

6 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

7 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

7 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

7 months ago - By: ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference